
- /
- Supported exchanges
- / US
- / IDXG.OTCQX
Interpace Biosciences Inc (IDXG OTCQX) stock market data APIs
Interpace Biosciences Inc Financial Data Overview
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Interpace Biosciences Inc data using free add-ons & libraries
Get Interpace Biosciences Inc Fundamental Data
Interpace Biosciences Inc Fundamental data includes:
- Net Revenue: 45 454 K
- EBITDA: 6 101 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Interpace Biosciences Inc News

Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available mole...


See Which Of The Latest 13F Filers Holds PH
At Holdings Channel, we have reviewed the latest batch of the 23 most recent 13F filings for the 06/30/2025 reporting period, and noticed that Parker Hannifin Corp (Symbol: PH) was held by 10 of these...

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts...

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
●Q2Revenue of $11.0 million;a 49% increase year-over-year; highest quarter in history ●Q2Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year d...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.